Innovative Industrial Properties Saturday Brief: Cannabis REIT Positioned as Rescheduling Unlocks Institutional Capital
TL;DR: Innovative Industrial Properties (NYSE: IIPR) — the cannabis sector’s only publicly traded REIT — is positioned to benefit as federal rescheduling progress begins normalizing the institutional risk calculus for cannabis-adjacent real estate. With MSOS sector equities at 2026 highs and operator balance sheets improving under reduced 280E burdens, demand for sale-leaseback financing is rising, […]
Trulieve Cannabis Saturday Brief: Florida Dominance and 280E Savings Create Multi-Year Earnings Leverage
TL;DR: Trulieve Cannabis (OTC: TCNNF) heads into the week of June 29 with a strengthened fundamental thesis as April’s federal medical rescheduling begins reducing its 280E tax burden. With the DOJ’s adult-use Schedule III hearings entering their final phase, Trulieve’s Florida-centric retail network — the largest single-state dispensary footprint in the U.S. — stands as […]
Cannabis Market Week-Ahead June 29: MSOS Locks 2026 Highs as Rescheduling Hearings Near Conclusion
TL;DR: Cannabis equities finished Friday, June 26 near session highs as the MSOS ETF extended its best weekly performance of 2026, buoyed by a second constructive day of DEA administrative rescheduling hearings. With the holiday-shortened week of June 29 ahead, investors will focus on rescheduling timeline developments, imminent Q2 earnings prints from top MSOs, and […]
Organigram Holdings Midday Review: BAT Partnership and EU Medical Exports Drive Q3 FY2026 Outperformance
TL;DR: Organigram Holdings (OGI) delivered strong Q3 FY2026 results, with net revenue of approximately C$52.3 million representing a 9% year-over-year gain, driven primarily by accelerating international medical cannabis exports to Germany and the United Kingdom. The British American Tobacco-backed Canadian LP continues to differentiate itself through its Centre of Excellence R&D program and export-first strategy […]
Green Thumb Industries Q2 2026 Earnings Preview: Free Cash Flow and 280E Savings in Focus
TL;DR: Green Thumb Industries (GTBIF) is set to report Q2 2026 results in late July, and analysts are watching three key metrics: free cash flow generation, the early financial impact of 280E relief from April’s medical rescheduling, and same-store sales trends across its 98 retail locations. With MSOS at 2026 highs and rescheduling hearings underway, […]
Cannabis Stocks Friday Morning: MSOS Extends 2026 Highs as Rescheduling Hearings Enter Day 2
TL;DR: Cannabis equities are maintaining elevated positions Friday morning as the Department of Justice adult-use rescheduling hearings enter a second day in Washington. The AdvisorShares Pure US Cannabis ETF (MSOS) has climbed 48.5% since the end of Q1, outpacing broader equity benchmarks, with multi-state operators leading the advance. Investors are watching the hearing proceedings closely, […]
280E in Two Acts: How April Medical Rescheduling Changed MSO Taxes and What Adult-Use Hearings Would Complete
TL;DR: The April 23 rescheduling of medical cannabis to Schedule III delivered the first real relief from Section 280E in the federal tax code’s three-decade grip on the cannabis industry. But for the largest multi-state operators — whose revenues are overwhelmingly adult-use — the more consequential change awaits the outcome of the ongoing DOJ adult-use […]
MSOS Sector Positions for a Pivotal Friday as DOJ Rescheduling Hearings Begin — Outlook for June 26
TL;DR: Thursday, June 25 delivered a trifecta of structural catalysts for the cannabis sector — DOJ rescheduling hearings formally opened, Tilray posted record international revenue, and Curaleaf cleared a major uplisting hurdle. With the MSOS sector holding near 2026 highs heading into Friday’s session, investors are now watching for hearing testimony and follow-through volume to […]
Tilray Brands Posts Record Q3 FY2026 Revenue as International Cannabis Surges 73%
TL;DR: Tilray Brands (Nasdaq: TLRY) reported record fiscal third-quarter revenue of $206.7 million for the period ending February 28, 2026, up 11% year-over-year, driven by a 73% surge in international cannabis revenue and steady gains across its Canadian and wellness segments. The company posted its first meaningful adjusted net income and reaffirmed full-year fiscal 2026 […]
DOJ Begins Adult-Use Cannabis Rescheduling Hearings — Full 280E Relief Now on the Table
TL;DR: The U.S. Department of Justice has opened formal hearings in late June 2026 to evaluate rescheduling adult-use cannabis from Schedule I, following the landmark April 23 move of medical cannabis to Schedule III. A successful outcome would eliminate 280E taxation entirely for multi-state operators (MSOs), potentially unlocking hundreds of millions in annual cash flow […]